15 Results for "

PK profiles

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "PK profiles" in MCE Product Catalog:

10
10 Cited Publications
Cat. No.: HY-135303
CAS No.: 1445847-37-9
Purity:  99.94%
Target:  

GPR84

Research Areas:  

Inflammation/Immunology

GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis . GLPG1205 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-137464A
CAS No.: 2088453-21-6
Purity:  99.11%
Target:  

Glycosidase

Research Areas:  

Inflammation/Immunology

OATD-01 is a highly potent, first-in-class, orally active and selective chitinase inhibitor with low nanomolar activity toward CHIT1 (hCHIT1,IC50=23 nM). OATD-01 shows excellect PK profile in multiple species and is selectivity against a panel of other off-targets. OATD-01 exhibits significant antifibrotic efficacy in vivo and can be used for pulmonary fibrosis (IPF) research .
loading...
    loading...
Cat. No.: HY-151813
CAS No.: 2947393-64-6
Purity:  99.35%
Target:  

Fluorescent Dye

Research Areas:  

Cancer

NNMT-IN-4 (compound 38) is a selective, uncompetitive and membrane permeability nicotinamide N-methyltransferase (NNMT) inhibitor with IC50 values of 42 and 38 nM in vitro biochemical and cell-based assays, respectively. NNMT-IN-4 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. NNMT-IN-4 can be used as a vivo chemical probe of NNMT .
loading...
    loading...
Cat. No.: HY-143889
CAS No.: 2375554-02-0
Purity:  98.82%
Target:  

CDK

Research Areas:  

Cancer

Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .
loading...
    loading...
Cat. No.: HY-112081
CAS No.: 2109805-96-9
Purity:  99.64%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

BAY-707, a chemical probe, is a substrate-competitive, highly potent and selective inhibitor of MTH1(NUDT1) with an IC50 of 2.3 nM. BAY-707 has a good pharmacokinetic (PK) profile to other MTH1 compounds and is well-tolerated in mice, but shows a clear lack of in vitro or in vivo anticancer efficacy .
loading...
    loading...
Cat. No.: HY-103266
CAS No.: 1245907-03-2
Purity:  99.57%
Target:  

Aurora Kinase

Research Areas:  

Cancer

TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .
loading...
    loading...
Cat. No.: HY-179004
CAS No.: 2640753-22-4
Synonyms: VU6022856
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ONO-9517601 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.067 μM, TREK-2 IC50= 0.23 μM). ONO-9517601 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-9517601 can be used for research on neurological and cognitive disorders .
loading...
    loading...
Cat. No.: HY-114147
CAS No.: 2219325-28-5
Purity:  98.50%
Target:  

Bacterial

Research Areas:  

Infection Inflammation/Immunology

Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 μg/mL) against agent-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability .
loading...
    loading...
Cat. No.: HY-116183
CAS No.: 1392116-37-8
Target:  

HCV

Research Areas:  

Infection

ITX 4520 is an orally active and potent hepatitis C virus inhibitor exhibiting an excellent PK profile in both rats and dogs .
loading...
    loading...
Cat. No.: HY-179005
CAS No.: 2640753-27-9
Synonyms: VU6024391
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ONO-7927846 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.11 μM, TREK-2 IC50= 0.29 μM). ONO-7927846 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-7927846 can be used for research on neurological and cognitive disorders .
loading...
    loading...
Cat. No.: HY-152535
CAS No.: 2935937-67-8
Target:  

HSV

Research Areas:  

Infection Inflammation/Immunology

ATV041 is an orally active Ibuprofen (HY-78131) and nucleotide analogue. ATV041 improves oral pharmacokinetic (PK) profile and tissue distribution with anti-mouse hepatitis virus (MHV) activity. ATV041 reduces viral load, tissue damage and virus-induced inflammation in a dose-dependent manner .
loading...
    loading...
Cat. No.: HY-149982
CAS No.: 2126853-16-3
IDO1-IN-22 (Compound 3) is a IDO1 inhibitor (biochemical hIDO1 IC50: 67.4 nM, HeLa hIDO1 IC50: 17.6 nM). IDO1-IN-22 has excellent antitumor efficacy in LLC xenograft model, as well as desirable pharmacokinetic (PK) profile .
loading...
    loading...
Cat. No.: HY-126321
CAS No.: 2377378-89-5
Target:  

ROR

Research Areas:  

Cancer

RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy .
loading...
    loading...
Cat. No.: HY-151915
CAS No.: 3012609-63-8
Target:  

ATM/ATR mTOR

Research Areas:  

Cancer

ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .
loading...
    loading...
Cat. No.: HY-157928
Target:  

Keap1-Nrf2

Research Areas:  

Inflammation/Immunology

Keap1-Nrf2-IN-18 (Compound 22) is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor with good pharmacokinetics (PK) profiles and more potent in vivo activities in rats. Keap1-Nrf2-IN-18 has the strongest inhibitory activity in structure−activity relationship (SAR) study (KD = 0.0029 μM) .
loading...
    loading...
  • 1